Kenneth Ferguson

Kenneth Ferguson

Director/Board Member presso CYCLACEL PHARMACEUTICALS, INC.

68 anni
Health Technology
Consumer Services
Finance

Profilo

Kenneth M.
Ferguson
is currently the Director at Cyclacel Pharmaceuticals, Inc. and an Operating Partner at Accelerator Services Corp.
Previously, he was the President, Chief Executive Officer & Director at Vactx International, Inc. from 2008 to 2010, COO, Chief Scientific Officer & Director at Lilly ICOS LLC, and President at ICOS Corp.
from 1990 to 2007.
He also served as the Chief Development Officer & Vice President at Omeros Corp.
from 2012 to 2017 and as the Chief Scientific Officer at EMulate Therapeutics, Inc. Dr. Ferguson received his undergraduate degree from Cornell University and his doctorate from Texas University of Health Center at San Antonio.

Posizioni attive di Kenneth Ferguson

SocietàPosizioneInizio
CYCLACEL PHARMACEUTICALS, INC. Director/Board Member 14/06/2022
Private Equity Investor -
Tutte le posizioni attive di Kenneth Ferguson

Precedenti posizioni note di Kenneth Ferguson

SocietàPosizioneFine
OMEROS CORPORATION Corporate Officer/Principal 01/05/2017
Vactx International, Inc. Chief Executive Officer 01/11/2010
President 01/12/2007
Chief Tech/Sci/R&D Officer -
Chief Tech/Sci/R&D Officer -
Vedi nel dettaglio l'esperienza di Kenneth Ferguson

Formazione di Kenneth Ferguson

Cornell University Undergraduate Degree
Texas University of Health Center at San Antonio Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Kenneth Ferguson

Relazioni

83

Relazioni di 1° grado

9

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa2
OMEROS CORPORATION

Health Technology

CYCLACEL PHARMACEUTICALS, INC.

Health Technology

Aziende private5

Health Technology

Health Technology

Health Technology

Finance

Vactx International, Inc.

Vedi le connessioni aziendali
  1. Borsa valori
  2. Insiders
  3. Kenneth Ferguson